1 December 2025
DLA Piper advises Aspen Neuroscience in Series C financing aimed at advancing personalized cell therapy programs
Advising firms
Deal team
3 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Randy Socol Lead | DLA Piper | Partner | Not stated | San Diego |
| Anthony Taranto | DLA Piper | Partner | Not stated | San Diego |
| Billy LaFortune | DLA Piper | Associate | Not stated | San Diego |
Stated terms
- Stated value
- USD 115m (US$115 million)
- What the figure measures
- Issue size
- Client
- Aspen Neuroscience, Inc.Issuer
- Counterparties
- OrbiMed (Investor)
ARCH Venture Partners (Investor)
Frazier Life Sciences (Investor)
Revelation Partners (Investor)
Medical Excellence Capital (Investor)
S32 (Investor)
Axon Ventures (Investor)
LYFE Capital (Investor)
LifeForce Capital (Investor)
Kite, a Gilead Company (Investor)
Balyasny Asset Management (Investor)
Cormorant Asset Management (Investor)
Prebys Ventures (Investor)